Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
3.390
+0.030 (0.89%)
At close: May 12, 2026, 4:00 PM EDT
3.300
-0.090 (-2.65%)
Pre-market: May 13, 2026, 4:53 AM EDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$81,000
Profits / Employee
-$1,965,600
Market Cap
7.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| Processa Pharmaceuticals | 12 |
| TransCode Therapeutics | 12 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 10 |
| Immuron | 7 |
| Acurx Pharmaceuticals | 4 |
| Xenetic Biosciences | 2 |
CANF News
- 22 hours ago - Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright - TheFly
- 12 days ago - Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months - GlobeNewsWire
- 6 weeks ago - Can-Fite BioPharma files to sell 3.29M ordinary shares for holders - TheFly
- 6 weeks ago - Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs - GuruFocus
- 6 weeks ago - Can-Fite BioPharma completes enrollment in Piclidenoson study - TheFly
- 6 weeks ago - Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - GlobeNewsWire
- 6 weeks ago - Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - GlobeNewsWire
- 2 months ago - Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment - GuruFocus